Gene Expressions and High Lymphocyte Count May Predict Durable Clinical Benefits in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Immune Checkpoint Inhibitors

SIMPLE SUMMARY: Despite the promising results not all patients with advanced non-small cell lung cancer benefit from immunotherapy. Immunotherapy may cause severe adverse events, and therefore, it is important to improve the selection of patients for this treatment. The current biomarker, PD-L1, is...

Descripción completa

Detalles Bibliográficos
Autores principales: Mouritzen, Mette T., Ladekarl, Morten, Hager, Henrik, Mattesen, Trine B., Lippert, Julie B., Frank, Malene S., Nøhr, Anne K., Egendal, Ida B., Carus, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526901/
https://www.ncbi.nlm.nih.gov/pubmed/37760450
http://dx.doi.org/10.3390/cancers15184480

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526901/
https://www.ncbi.nlm.nih.gov/pubmed/37760450
http://dx.doi.org/10.3390/cancers15184480

Ejemplares similares